Matthew Eagleton, MD, is an accomplished vascular surgeon who treats all aspects of peripheral vascular disease. He is an international expert on the treatment of complex aortic disease with endovascular therapy. He is the chief of the Division of Vascular and Endovascular Surgery and co-director of the Fireman Vascular Center at Massachusetts General Hospital, and leads a multidisciplinary team that manages vascular disease. In addition, he is co-director of the Mass General Thoracic Aortic Center.

Dr. Eagleton received his medical degree in 1994 and completed his general surgery residency in 2000, both at the University of Rochester. In 2002, he completed specialty training in vascular surgery at the University of Michigan and obtained advanced training in endovascular procedures at the Cleveland Clinic. Prior to his current role at Mass General, Dr. Eagleton was a professor of surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and vice-chairman of the Department of Vascular Surgery and director of vascular surgery at the Cleveland Clinic Aortic Center. In addition, he held the role of program director, overseeing the educational program for the Cleveland Clinic’s Integrated Residency (0+5), Independent Fellowship (5+2) training programs in vascular surgery and their Endovascular Mini-fellowship and Aortic Fellowship.

Dr. Eagleton has served in a variety of national organizations including the Vascular and Endovascular Surgical Society and the Society for Vascular Surgery. He just completed a four-year term as chair of the program committee for the Vascular Annual Meeting of the Society for Vascular Surgery.

Dr. Eagleton conducts clinical research evaluating the use of fenestrated and branched aortic endograft technology to treat complex aortic disease through a physician-sponsored investigational device exemption trial. In addition, he has been involved in numerous endograft clinical trials serving as an investigator, national principal investigator and advisor. He collaborates with a team of physicians, both locally and internationally, to better understand how to provide safer, more durable treatment options to patients with life-threatening aortic disease. Dr. Eagleton serves as director of the scientific advisory board for Centerline Biomedical and he serves on the scientific advisory board for ViTAA and Nectero, which are biomedical research companies aimed at developing improved treatment options for patients with vascular disease.

In his personal life, Dr. Eagleton enjoys cooking with sous vide and running. He is also a member of the Sons of the American Revolution.